Pfizer Signs $495M China Obesity Drug Deal With Sciwind
Pfizer has agreed to pay up to $495 million to obtain rights in China to an experimental obesity drug developed by Sciwind Biosciences. The deal grants Pfizer development and commercialization rights in mainland China as it expands its metabolic disease portfolio. The agreement comes amid growing global demand for weight-loss treatments and follows recent clinical progress in Pfizer’s obesity drug pipeline.